ストックスクリーナーアプリを入手
114.20
1.04%
1.17
アフターアワーズ：
114.24
0.04
+0.04%
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Mirum Pharmaceuticals Inc (MIRM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mirum Pharmaceuticals Market Sentiment - Benzinga España
Mirum Pharmaceuticals, Inc. Revenue Breakdown – BIVA:MIRM - TradingView
MIRM|Mirum Pharmaceuticals Inc|Price:113.030|Chg%:-1.330 - TradingKey
Mirum Pharmaceuticals, Inc. (MIRM) options chain - Yahoo Finance UK
Stifel reiterates Mirum Pharmaceuticals stock rating after rival trial fails - Investing.com
Stifel reiterates Mirum Pharmaceuticals stock rating after rival trial fails By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Inc (MIRM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Exploring a 25.62% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Why (MIRM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Citizens reiterates Mirum Pharmaceuticals stock rating on revenue outlook By Investing.com - Investing.com Canada
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Arcutis Expands Board of Directors with Appointment of Chris Peetz - GlobeNewswire Inc.
MIRM5806400 Bond Risk Profile - TradingView
US604749AB7 Bond Coupon Profile — Rate & Payments - TradingView
US604749AB7 Bond Profile — Key Metrics - TradingView
US604749AC5 Bond Profile — Key Metrics - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Insider Sell Alert: Eric Bjerkholt Sells 5,000 Shares of Mirum P - GuruFocus
Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing - Moomoo
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing - Moomoo
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares after exercising options - Stock Titan
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals outlines its liver disease focus as shares trade on Nasdaq - AD HOC NEWS
RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating - marketscreener.com
Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM) - Stock Titan
Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM) - Stock Titan
Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio - Seeking Alpha
MIRMMirum Pharmaceuticals Inc Latest SEC Filings - Finviz
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum Pharmaceuticals SVP sells $326,520 in common stock By Investing.com - Investing.com South Africa
Form 4 Mirum Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Mirum Pharmaceuticals SVP sells $326,520 in common stock - Investing.com
Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD - Investing.com
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125 - Moomoo
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib - Yahoo Finance
Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
2,721 performance shares proposed; Jolanda Howe sold 2,594 (MIRM) - Stock Titan
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):